Kaiser E, Petit D, Quinot J F, Suppini A, Sallaberry M
Département d'Anesthésie-Réanimation-Centre de brûlés, Hôpital d'Instruction des Armées Sainte-Anne, Toulon Naval.
Ann Fr Anesth Reanim. 1995;14(6):505-7. doi: 10.1016/s0750-7658(05)80492-7.
Mivacurium is a new neuromuscular blocking agent with a short acting time of about 30 min, due to a fast hydrolysis by pseudocholinesterases. This metabolism carries a risk for prolonged neuromuscular block in case of an acquired or congenital pseudocholinesterase deficiency. We report the case of a 75-year-old woman who experienced a neuromuscular block prolonged for 10 h after a single dose of 0.35 mg.kg-1 of mivacurium, because of a major pseudocholinesterase (1800 UI.L-1, normal value: 5400-13200 UI.L-1). The likely cause was a congenital deficiency by a homozygote genetic mutation, as usual causes of an acquired deficiency had been eliminated.
米库氯铵是一种新型神经肌肉阻滞剂,作用时间短,约为30分钟,这是由于其能被假性胆碱酯酶快速水解。如果存在获得性或先天性假性胆碱酯酶缺乏,这种代谢会带来神经肌肉阻滞延长的风险。我们报告了一例75岁女性的病例,该患者在单次静脉注射0.35 mg·kg-1米库氯铵后,神经肌肉阻滞延长至10小时,原因是严重的假性胆碱酯酶缺乏(1800 UI·L-1,正常值:5400 - 13200 UI·L-1)。由于已排除获得性缺乏的常见原因,可能的病因是纯合子基因突变导致的先天性缺乏。